Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of treatment of chronic hepatitis c virus patients with direct-acting anti-retroviral drugs on semen and hormonal parameters

  • Yosra H. Mahmoud (Department of Clinical Pathology, Gastrointerology and Infectious Diseases, National Hepatology and Tropical Medicine Research Institute) ;
  • Basem Eysa (Department of Hepatology, Gastrointerology and Infectious Diseases, National Hepatology and Tropical Medicine Research Institute) ;
  • Eman Mohamed Salah Ahmed (Department of Dermatology, Andrology, Sexual Medicine and STDS, Faculty of Medicine, Helwan University) ;
  • Heba Abdelaziz (Public Health Department, National Hepatology and Tropical Medicine Research Institute) ;
  • Ashgan Mohamed Zayed (Department of Medical Microbiology, Faculty of Medicine, PortSaid University) ;
  • Amin Abdel Baki (Department of Hepatology, Gastrointerology and Infectious Diseases, National Hepatology and Tropical Medicine Research Institute) ;
  • Ahmed Hosny (Department of Dermatology, Andrology, Sexual Medicine and STDS, Faculty of Medicine, Helwan University) ;
  • Mohamed Hassany (Tropical Medicine Department, National Hepatology and Tropical Medicine Research Institute)
  • Received : 2023.12.12
  • Accepted : 2024.02.22
  • Published : 2024.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: Hepatitis C virus (HCV) infection is known to influence the seminal and hormonal parameters of infected men. This study was performed to assess the effects of HCV clearance using direct-acting antiviral (DAA) agents on semen and hormonal parameters. Methods: A total of 50 patients with chronic HCV were enrolled, and conventional semen analysis was performed according to World Health Organization guidelines. Basal levels of total testosterone, free testosterone (FT), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), prolactin, and sex hormone-binding globulin (SHBG) were assessed before and 3 months after treatment with DAAs. Results: Following DAA treatment, statistically significant increases were observed in sperm motility and the proportion of grade A sperm. Additionally, the percentage of abnormal forms was significantly decreased after treatment (p=0.000). However, no significant differences were observed in semen volume, concentration, or total sperm count. Sex hormone analysis of patients after DAA treatment revealed significant increases in FT, LH, and FSH levels, along with significant decreases in SHBG, prolactin, and E2 levels. Conclusion: Following HCV clearance, we noted an improvement in sperm motility and an increase in the percentage of sperm with normal morphology. Treatment with DAAs was also associated with increased levels of FT and LH, along with decreased levels of SHBG, prolactin, and E2.

Keywords

References

  1. Akhigbe RE, Dutta S, Hamed MA, Ajayi AF, Sengupta P, Ahmad G. Viral infections and male infertility: a comprehensive review of the role of oxidative stress. Front Reprod Health 2022;4:782915. https://doi.org/10.3389/frph.2022.782915
  2. Savasi V, Parrilla B, Ratti M, Oneta M, Clerici M, Ferrazzi E. Hepatitis C virus RNA detection in different semen fractions of HCV/HIV-1 co-infected men by nested PCR. Eur J Obstet Gynecol Reprod Biol 2010;151:52-5. https://doi.org/10.1016/j.ejogrb.2010.03.011
  3. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-42. https://doi.org/10.1002/hep.26141
  4. Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis 2007;196:1474-82. https://doi.org/10.1086/522608
  5. Cacoub P, Saadoun D. Extrahepatic manifestations of chronic HCV infection. N Engl J Med 2021;384:1038-52. https://doi.org/10.1056/NEJMra2033539
  6. Durazzo M, Premoli A, Di Bisceglie C, Bertagna A, Faga E, Biroli G, et al. Alterations of seminal and hormonal parameters: an extrahepatic manifestation of HCV infection? World J Gastroenterol 2006;12:3073-6. https://doi.org/10.3748/wjg.v12.i19.3073
  7. Bourlet T, Lornage J, Maertens A, Garret AS, Saoudin H, Tardy JC, et al. Prospective evaluation of the threat related to the use of seminal fractions from hepatitis C virus-infected men in assisted reproductive techniques. Hum Reprod 2009;24:530-5. https://doi.org/10.1093/humrep/den414
  8. Lorusso F, Palmisano M, Chironna M, Vacca M, Masciandaro P, Bassi E, et al. Impact of chronic viral diseases on semen parameters. Andrologia 2010;42:121-6. https://doi.org/10.1111/j.1439-0272.2009.00970.x
  9. Hofny ER, Ali ME, Taha EA, Nafeh HM, Sayed DS, Abdel-Azeem HG, et al. Semen and hormonal parameters in men with chronic hepatitis C infection. Fertil Steril 2011;95:2557-9. https://doi.org/10.1016/j.fertnstert.2011.05.014
  10. Nguyen HV, Mollison LC, Taylor TW, Chubb SA, Yeap BB. Chronic hepatitis C infection and sex hormone levels: effect of disease severity and recombinant interferon-alpha therapy. Intern Med J 2006;36:362-6. https://doi.org/10.1111/j.1445-5994.2006.01093.x
  11. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206. https://doi.org/10.1056/NEJMoa1010494
  12. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16. https://doi.org/10.1056/NEJMoa1012912
  13. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17. https://doi.org/10.1056/NEJMoa1009482
  14. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28. https://doi.org/10.1056/NEJMoa1013086
  15. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-24. https://doi.org/10.1056/NEJMoa1014463
  16. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson D, Zeuzem S, et al. 3 Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333+/- ribavirin in patients with chronic HCV GT1 infection: results from the aviator study. J Hepatol 2013;58(Suppl 1):S2. https://doi.org/10.1016/S0168-8278(13)60005-7
  17. Everson GT, Sims KD, Rodriguez-Torres M, H'ezode C, Lawitz E, Bourliere M, et al. 1423 Interim analysis of an interferon (IFN)- and ribavirin (RBV)-free regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 in treatment-naive, hepatitis C virus genotype 1-infected patients. J Hepatol 2013;58(Suppl 1):S573.
  18. Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Mullhaupt B, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013;369:630-9. https://doi.org/10.1056/NEJMoa1213557
  19. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-77. https://doi.org/10.1056/NEJMoa1214854
  20. McQuaid T, Savini C, Seyedkazemi S. Sofosbuvir, a significant paradigm change in HCV treatment. J Clin Transl Hepatol 2015;3:27-35. https://doi.org/10.14218/JCTH.2014.00041
  21. El Kassas M, Salah E, Gad A, Hosny A. Improvement of sexual dysfunction in patients after treatment of hepatitis C virus using directly acting antivirals. Curr Med Res Opin 2021;37:967-72. https://doi.org/10.1080/03007995.2021.1901677
  22. Chaudhury CS, Mee T, Chairez C, McLaughlin M, Silk R, Gross C, et al. Testosterone in men with chronic hepatitis c infection and after hepatitis C viral clearance. Clin Infect Dis 2019;69:571-6. https://doi.org/10.1093/cid/ciy965
  23. Fusco F, D'Anzeo G, Rossi A, Sciorio C, Buonomo AR, d'Emmanuele di Villa Bianca R, et al. Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature. Expert Opin Pharmacother 2013;14:2533-44. https://doi.org/10.1517/14656566.2013.850073
  24. Liu S, Sun Q. Sex differences, endogenous sex-hormone hormones, sex-hormone binding globulin, and exogenous disruptors in diabetes and related metabolic outcomes. J Diabetes 2018;10:428-41. https://doi.org/10.1111/1753-0407.12517
  25. Hammond GL. Plasma steroid-binding proteins: primary gatekeepers of steroid hormone action. J Endocrinol 2016;230:R13-25. https://doi.org/10.1530/JOE-16-0070
  26. Safarinejad MR, Kolahi AA, Iravani S. Evaluation of semen variables, sperm chromosomal abnormalities and reproductive endocrine profile in patients with chronic hepatitis C. BJU Int 2010;105:79-86. https://doi.org/10.1111/j.1464-410X.2009.08720.x
  27. Ghanem HM, Ismaeel NN, Haseeb AF, Nabawy WM, Rehan M, Shreen H. Seminal parameters before and during combined antiviral (pegylated interferon α-2a and ribavirin) treatment in chronic hepatitis C virus patients in upper Egypt. Egypt J Intern Med 2014;26:104-9. https://doi.org/10.4103/1110-7782.145302
  28. Hofer H, Donnerer J, Sator K, Staufer K, Scherzer TM, Dejaco C, et al. Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy. J Hepatol 2010;52:812-6. https://doi.org/10.1016/j.jhep.2009.12.039